The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation.
In vitro studies have shown possible antiviral effects of tyrosine kinase inhibitors. In a retrospective study, we show that use of the tyrosine kinase inhibitor imatinib does not appear to reduce cytomegalovirus reactivation during the first 100 days after transplantation in a cohort of hematopoietic cell transplant recipients.
Travi
Giovanna
G
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Pergam
Steven A
SA
Xie
Hu
H
Carpenter
Paul
P
Kiem
Hans-Peter
HP
Corey
Lawrence
L
Boeckh
Michael J
MJ
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D001549:Benzamides; D003587:Cytomegalovirus / Q000502:physiology*; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000517:prevention & control*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use*; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods; D014775:Virus Activation / Q000187:drug effects*; D055815:Young Adult
D000998:Antiviral Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate